Intraocular penetration of topical tissue plasminogen activator.
Fifty-eight eyes of 31 anesthetized rabbits received one drop of proparacaine hydrochloride, 0.05%, and two drops of tissue plasminogen activator (tPA) separated by 5 minutes. Four eyes of two additional rabbits had epithelial defects created before drug delivery. Tissue plasminogen activator in multiple doses was given to eight eyes of four other rabbits. We used this dosing regimen to investigate the effect of topical tPA on anterior chamber fibrin clots in three rabbits. A two-site enzyme-linked immunosorbent assay test was used to measure tPA levels in the aqueous samples, obtained by paracentesis in each eye. Of 53 eyes treated with the original dosing regimen, 21 (40%) had detectable tPA aqueous levels. Blood and aqueous from eyes of untreated control rabbits, contralateral control eyes of treated rabbits, and eyes with epithelial defects had nondetectable tPA. Multiple tPA drop dosing resulted in 75% of aqueous samples with detectable tPA and a higher average tPA concentration than the original dosing regimen. Eyes treated with tPA showed a significantly faster resolution of anterior chamber fibrin clots than did control eyes.
Lim
J I
JI
Department of Ophthalmology, University of Illinois, College of Medicine, Chicago.
Fiscella
R
R
Tessler
H
H
Gagliano
D A
DA
Chaques-Alepuz
V
V
Mohler
M A
MA
D000287:Administration, Topical; D000818:Animals; D000867:Anterior Chamber / Q000378:metabolism; D001082:Aqueous Humor / Q000378:metabolism*; D003315:Cornea / Q000187:drug effects*; D004797:Enzyme-Linked Immunosorbent Assay; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D011817:Rabbits; D010959:Tissue Plasminogen Activator / Q000493:pharmacokinetics*
D005338:Fibrin Fibrinogen Degradation Products; D010959:Tissue Plasminogen Activator